Treatment of Central Sleep Apnea with Adaptive Servoventilation in Chronic Heart Failure

摘要

Patients with chronic heart failure (CHF) and systolic dysfunction are at increased risk of having central sleep apnea (CSA) and Cheyne-Stokes respiration, which are associated with hypoxemia, sleep fragmentation, and mortality. Positive pressure devices (adaptive servoventilation or autoservoventilation [ASV]) have been designed to treat CSA and are often used in this patient population. These devices provide ventilatory support during periods of central apneas and hypopneas. ASV has been shown to be effective in improving sleep apnea severity, sleep quality, and cardiac function in short-term clinical trials. Given these short-term benefits, long-term treatment was hypothesized to result in improvements in robust clinical endpoints in patients with CHF.